Search Results - "Hall, Malloury"

CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma by Sauter, Craig S., Senechal, Brigitte, Rivière, Isabelle, Ni, Ai, Bernal, Yvette, Wang, Xiuyan, Purdon, Terence, Hall, Malloury, Singh, Ashvin N., Szenes, Victoria Z., Yoo, Sarah, Dogan, Ahmet, Wang, Yongzeng, Moskowitz, Craig H., Giralt, Sergio, Matasar, Matthew J., Perales, Miguel-Angel, Curran, Kevin J., Park, Jae, Sadelain, Michel, Brentjens, Renier J.

“…High-dose chemotherapy and autologous stem cell transplantation (HDT-ASCT) is the standard of care for relapsed or primary refractory (rel/ref) chemorefractory…”
Get full text

A Phase I First-in-Human Clinical Trial of CD19-Targeted 19-28z/4-1BBL “Armored” CAR T Cells in Patients with Relapsed or Refractory NHL and CLL Including Richter's Transformation by Park, Jae H., Palomba, Maria Lia, Batlevi, Connie Lee, Riviere, Isabelle, Wang, Xiuyan, Senechal, Brigitte, Furman, Richard R., Bernal, Yvette, Hall, Malloury, Pineda, John, Diamonte, Claudia, Halton, Elizabeth, Brentjens, Renier J., Sadelain, Michel

“…Background: CD19-specific 2nd generation chimeric antigen receptor (CAR) T cell therapy with either CD28 or 41BB co-stimulatory domain has demonstrated…”
Get full text

Intestinal Microbiota Composition Prior to CAR T Cell Infusion Correlates with Efficacy and Toxicity by Smith, Melody, Littmann, Eric R., Slingerland, John B., Clurman, Annelie, Slingerland, Ann E., Taur, Ying, Schluter, Jonas, Park, Jae H., O'Cearbhaill, Roisin, Mailankody, Sham, Smith, Eric L., Palomba, Maria Lia, Yeku, Oladapo, Peled, Jonathan U., Halton, Elizabeth, Diamonte, Claudia, Chan, Jason, Hall, Malloury, Anant, Pavan, Kane, Peter, Giralt, Sergio, Riviere, Isabelle, Brentjens, Renier J., Pamer, Eric G., van den Brink, Marcel R.M.

“…Introduction Cellular therapy with chimeric antigen receptor (CAR) T cells has fundamentally changed the treatment of many cancers. Unfortunately, not all…”
Get full text